Arcturus Therapeutics (ARCT) Misses Q3 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
UPDATE: Arcturus Therapeutics (ARCT) PT Raised to $30 at Goldman Sachs (CORRECTION)
November 9, 2021 6:51 AM EST(Updated - November 9, 2021 6:52 AM EST)
Goldman Sachs analyst Madhu Kumar raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $30.00 (from $28.00) while maintaining a Sell rating.
... More